Charles River Laboratories International vs ICON
CRL and ICLR side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRL and ICLR compare
ICON grew revenue faster over the last twelve months (1.7% versus −0.74% for Charles River Laboratories International).
ICON keeps more of each dollar of sales as profit, with a net margin of 0.51% compared with −6.0% at Charles River Laboratories International.
Charles River Laboratories International scores higher on the StockData Score (7 against 4 for ICON), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRL | ICLR |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | – |
| Share price | $359.41 | $211.36 |
| Change, 1 year | 99.5% | 27.4% |
| Change, 5 years | −4.2% | −20.5% |
| Beta (5Y) | 1.19 | 1.24 |
| Employees | 20K | 40K |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.3× | – |
| P/B | 6.0× | – |
| EV/EBITDA | 50.5× | – |
| P/FCF | 46.3× | – |
| FCF yield | 2.2% | – |
| Fair value | $80.65 | – |
| Margin of safety | −346% | – |
| Growth | ||
| Revenue growth (TTM) | −0.74% | 1.7% (better) |
| Revenue growth, 5Y average | 6.5% | 24.2% (better) |
| Net income growth (TTM) | – | −95.1% |
| EPS growth (TTM) | – | −94.8% |
| EPS growth, 5Y average | – | −14.0% |
| Profitability | ||
| Gross margin | – | 23.9% |
| Operating margin | 2.3% | 3.6% (better) |
| Net margin | −6.0% | 0.51% (better) |
| FCF margin | 9.3% | 10.7% (better) |
| Return on equity | −7.7% | 0.45% (better) |
| Return on invested capital | 1.3% | 2.0% (better) |
| Financial health | ||
| Debt / equity | 0.92 | 0.23 (better) |
| Net debt / EBITDA | 6.27 | 1.77 (better) |
| Interest coverage | 0.8× | 1.5× (better) |
| Current ratio | 1.35 (better) | 0.95 |
| Altman Z-score | 3.11 | – |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 1.9% | – |
| Shareholder yield | 1.9% | – |
| Ownership | ||
| Held by institutions | 119% | 105% |
| Held by insiders | 1.2% | 0.57% |
| Insider net buying, 12 months | −$42.6M | −$4.0M (better) |
| Superinvestors holding | 1 | 4 (better) |
| Short interest, % of float | 6.1% | 3.7% |
Go deeper
- CRL stock overview
- CRL income statement
- CRL valuation and score
- ICLR stock overview
- ICLR income statement
- ICLR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.